FDA approves Clearside's XIPERE for macular edema associated with uveitis; first suprachoroidal therapy

Clearside Biomedical, Inc.

XIPERE (triamcinolone acetonide injectable suspension) is the first FDA-approved therapy for suprachoroidal injection.
Phase 3 PEACHTREE trial: 47% of XIPERE patients achieved ≥15-letter BCVA improvement vs 16% sham (p<0.01) at Week 24.
Bausch + Lomb markets XIPERE; expected availability Q1 2022 under Clearside's SCS Microinjector delivery system.
This is Clearside's first commercial product and the first approved treatment specifically for macular edema associated with uveitis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.